Xenon Pharmaceuticals (STU:XP0) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XP0 Xenon Pharmaceuticals Inc STU:XP0
27 GF Score
Price €52.00
GF Value €0.14
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

STU:XP0
27GF Score
Xenon Pharmaceuticals Inc STU:XP0
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xenon Pharmaceuticals (STU:XP0) Overvalued in 2026?

Based on GuruFocus' analysis, Xenon Pharmaceuticals stock appears to be overvalued. The current stock price of €52.00 is trading 37042.9% above its estimated GF Value™ of €0.14. GuruFocus considers Xenon Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:XP0:

  • Interest Expense (Positive):
  • GF Value™: €0.14 vs. price of €52.00 (37042.9% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the STU:XP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xenon Pharmaceuticals Business Description

Other Exchanges XENE:USA
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
27GF Score

Get the complete analysis for STU:XP0

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€52.00
Price
€0.14
GF Value